Author:Qingfeng Pharmaceutical Group
Posted Time:2025-01-16 00:00
On January 16, Qingfeng Pharmaceutical Group’s subsidiary, Kvvit Pharmaceuticals, and Kexing Biopharm (688136.SH) officially signed an agreement to work together on the international promotion of Enzalutamide Soft Capsules. This marks the second collaboration between the two companies following their April 2024 licensing agreement for the international promotion of Olaparib tablets. Under the agreement, Qingfeng Pharmaceutical grants Kexing Biopharm exclusive marketing rights for Enzalutamide Soft Capsules across 11 overseas markets, including Brazil, Argentina, and Colombia.
About Enzalutamide Soft Capsules
Enzalutamide soft capsules are indicated for adult patients with advanced prostate cancer, including those with non-metastatic castration-resistant prostate cancer (NM-CRPC) at high risk of metastasis, as well as asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) patients who have failed androgen deprivation therapy (ADT) and have not undergone chemotherapy.
According to the International Agency for Research on Cancer (IARC), there were approximately 1.5 million new prostate cancer cases worldwide in 2022, ranking it as the second most prevalent cancer among men globally. Incidence increases with age—it begins to rise at around age 50 years of age and peaks between 65 and 80. Analysis by Medical Lens indicates that prostate cancer (PCa) is the most common male cancer in Europe, North America, Oceania, and sub-Saharan Africa, the top type of cancer in 114 countries, and the leading cause of cancer death in 56 countries. From 2007 to 2017, global incidence of PCa increased by 42%. In Brazil, there are 62 new cases per 100,000 men. Incidence is even higher in developed regions and among African American men. In 2022, prostate cancer accounted for 23.2% of new male cancer cases across 27 EU countries.
As a next-generation therapy for prostate cancer, enzalutamide offers good efficacy and safety, and is currently the most widely indicated androgen receptor (AR) inhibitor. It is able to meet massive market demands and can synergize with the partnered drug Olaparib for combination therapy in metastatic castration‑resistant prostate cancer (mCRPC) with HRR gene mutations. According to Menet data, global sales of enzalutamide exceeded USD 5 billion in 2023.
Qingfeng Pharmaceutical has maintained a long-standing focus on oncology, with a growing portfolio of approved therapies including abiraterone, sorafenib, afatinib, enzalutamide, lenvatinib, palbociclib, regorafenib, and olaparib.
Qingfeng’s enzalutamide soft capsules received U.S. FDA approval on September 26, 2023, followed by China NMPA approval on June 25, 2024—marking the company’s first drug approved for clinical use \in both the U.S. and China.
Qingfeng is fast-tracking its global development strategy. Over the next five years, the company plans to register and commercialize more than ten products across the U.S., Europe, and emerging markets, aiming to offer better treatment options and services to patients worldwide. This renewed collaboration between Qingfeng Pharmaceutical and Kexing Biopharm reflects the mutual trust and recognition built on their successful existing partnership. This partnership underscores another significant breakthrough in the internationalization of Qingfeng Pharmaceutical’s high-end formulations. It will positively impact the company’s overseas expansion, increasing product accessibility and ultimately benefitting patients worldwide.
About Kexing Biopharm
Kexing Biopharm Co.,Ltd. (ticker: 688136.SH) is an innovative and internationally-oriented biopharmaceutical company specializing in the R&D, manufacture and sales of recombinant protein drugs and microbiome therapeutics. The company focuses on therapies for infectious diseases, oncology & immunology, hematology, gastroenterology, and degenerative diseases. It boasts cutting-edge platforms—including novel proteins, antibodies, and nucleic acid drugs—and pursues a dual “innovation + globalization” strategy. Kexing Biopharm also explores biotech applications across the broader health sector and invests in emerging fields like animal vaccines and synthetic biology, aiming to take the lead in high-quality biologics and serve patients throughout the world. Its core products lead their categories in China, supplying nearly 7,000 tertiary hospitals and approximately 20,000 healthcare facilities nationwide. Products have received market approval in nearly 40 countries—including Brazil, the Philippines, and Indonesia—and are already marketed there.
